PTIX (Protagenic Therapeutics) 5-Year ROIIC % : 1,395.75% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
22 GF Score
Price $0.18
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics 5-Year ROIIC %?

Protagenic Therapeutics PTIX +8.02% 22 5-Year ROIIC % is 1,395.75 as of Dec. 2024. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,171 Biotechnology companies, Protagenic Therapeutics ranks better than 96.75% on this metric.

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Protagenic Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2024 was 1,395.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Protagenic Therapeutics's 5-Year ROIIC % or its related term are showing as below:

PTIX's 5-Year ROIIC % is ranked better than
96.75% of 1171 companies
in the Biotechnology industry
Industry Median: -11.04 vs PTIX: 1395.75

Protagenic Therapeutics  (OTCPK:PTIX) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Protagenic Therapeutics 5-Year ROIIC % Related Terms


Protagenic Therapeutics 5-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics 5-Year ROIIC % Chart

Protagenic Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,513.41 0.00 1,454.88 399.46 1,395.75

Protagenic Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,395.75 0.00 0.00 0.00 0.00

PTIX vs CERO, CYTOF, CARM: 5-Year ROIIC % Comparison

For the Biotechnology subindustry, Protagenic Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics 5-Year ROIIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's 5-Year ROIIC % falls into.


PTIX
22GF Score
Protagenic Therapeutics Inc PTIX
5-Year ROIIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics 5-Year ROIIC % Calculation

Protagenic Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -5.701 (Dec. 2024) - -2.086 (Dec. 2019) )/( 0.073 (Dec. 2024) - 0.332 (Dec. 2019) )
=-3.615/-0.259
=1,395.75%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 5-Year ROIIC % →
What does a 5-Year ROIIC % of 1,395.75 mean?
Protagenic Therapeutics (PTIX) has a 5-Year ROIIC % of 1,395.75 as of Dec. 2024. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Protagenic Therapeutics and its competitors. According to the industry distribution chart, Protagenic Therapeutics ranks #38 out of 1171 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Protagenic Therapeutics' 5-Year ROIIC % too high?
Protagenic Therapeutics' current 5-Year ROIIC % is 1,395.75. Based on the distribution chart, Protagenic Therapeutics ranks #38 out of 1171 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' 5-Year ROIIC % compare to CERO and CYTOF?
According to the Biotechnology industry distribution chart, Protagenic Therapeutics ranks #38 out of 1171 companies for 5-Year ROIIC %. This places Protagenic Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current 5-Year ROIIC % is 1,395.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current 5-Year ROIIC % of 1,395.75. The current 5-Year ROIIC % is 1,395.75. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current 5-Year ROIIC % is 1,395.75 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score

Get the complete analysis for PTIX

5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price